Peter J. van Roessel, Giacomo Grassi, Elias N. Aboujaoude, José M. Menchón, Michael Van Ameringen, Carolyn I. Rodríguez. Treatment-resistant OCD: Pharmacotherapies in adults,
Comprehensive Psychiatry, Volume 120, 2023,152352, ISSN 0010-440X, https://doi.org/10.1016/j.comppsych.2022.152352.
- Many individuals with OCD do not sufficiently benefit from first-line treatment with serotonin reuptake inhibitors.
- A broad range of pharmacotherapies have been explored as adjunctive or alternative interventions for treatment-resistant OCD.
- Glutamatergic and anti-inflammatory interventions, among others, may offer favorable benefit to risk profiles.
- Dopamine antagonist treatments remain the best evidenced augmentation strategy for treatment-resistant OCD.
Gabriella True
